FUJIFILM Diosynth Biotechnologies was recently awarded the Global Biotechnology Award from IChemE (Institute of Chemical Engineers) Award Ceremony held in Manchester, England. The award recognizes achievement, innovation and discoveries in the fields of biochemical, biomedical, bioprocessing, bioengineering, bioenergy, biocatalysis, bioreactor and nanotechnology.

We submitted our new multi-product high potency unit at Billingham for the award (we refer to it as MF3) and it was recognized as the winner against entries from USA, Ireland, Australia, Brazil, Singapore and UK.

Below is an excerpt of our facility:

cGMP manufacture of high potency biologics – FUJIFILM Diosynth Biotechnogies, UK

High potency biologics-based medicines will become an increasingly important source of new pharmaceuticals, offering higher efficacy at lower doses while reducing side effects. Demanding regulatory constraints on these types of drugs have traditionally led producers to build facilities dedicated to single products, increasing the barrier-to-entry and ultimately preventing the production of potentially life-changing therapeutics. Using a new engineering and operational approach, Fujifilm has developed a multi-product facility that uses novel technology for containment and assured degradation. This ensures there is a world class facility providing long-term opportunities for the manufacture of these important medicines.